重组人血管内皮抑制素在女性恶性肿瘤治疗中的临床应用  

Application of Recombinant Human Endostatin in Treatment of Female Malignant Tumors

作　　者：赖军明 林红[2] 罗辉[2] 胡爽 LAI Junming;LIN Hong;LUO Hui;HU Shuang(2015 Grade of Medical Department of Graduate School Nanchang University,Nanchang 330006,China;Department of Oncology of the First Affiliated Hospital,Nanchang University,Nanchang 330006,China;Department of Oncology of the 171 st Hospital of Chinese Peole’s Libration Army,Jiujiang 332000,China)

机构地区：[1]南昌大学研究生院医学部,南昌330006 [2]南昌大学第一附属医院肿瘤科,南昌330006 [3]中国人民解放军第171医院肿瘤科,江西九江332000

出　　处：《实用临床医学（江西）》2017年第11期104-107,共4页Practical Clinical Medicine

摘　　要：重组人血管内皮抑素(rh-endostatin,商品名:恩度)是一种广谱的抗血管生成分子靶向药物,主要通过抑制血管内皮细胞增值和迁移来抑制肿瘤生长。近年来,恩度用于治疗女性恶性肿瘤的研究逐渐增多,并取得了较好的疗效,且毒副作用小。本文就近年恩度在女性恶性肿瘤治疗中的应用研究进展进行综述。Recombinant human endostatin(Endostar),a broad spectrum drug targeting angiogenesis,can inhibit tumor growth by suppressing the proliferation and migration of vascular endothelial cells.In recent years,there is a gradual increase in the treatment of female malignant tumors with Endostar,which produces good efficacy and little toxicity.This paper reviews the recent progress in clinical application of Endostar in the treatment of female malignant tumors.

关 键 词：重组人血管内皮抑素 恩度 乳腺癌 宫颈癌 卵巢癌 临床应用 

分 类 号：R737.3[医药卫生—肿瘤]